MXPA05013973A - Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. - Google Patents

Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.

Info

Publication number
MXPA05013973A
MXPA05013973A MXPA05013973A MXPA05013973A MXPA05013973A MX PA05013973 A MXPA05013973 A MX PA05013973A MX PA05013973 A MXPA05013973 A MX PA05013973A MX PA05013973 A MXPA05013973 A MX PA05013973A MX PA05013973 A MXPA05013973 A MX PA05013973A
Authority
MX
Mexico
Prior art keywords
methods
prophylactic
mhc class
immune responses
therapeutic purposes
Prior art date
Application number
MXPA05013973A
Other languages
English (en)
Inventor
Kent Andrew Smith
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MXPA05013973A publication Critical patent/MXPA05013973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

Modalidades relacionadas a los metodos y composiciones para producir, mejorar y sustentar respuestas, inmunes preferentemente contra epitopes restringidos de MHC clase I Los metodos y composiciones pueden utilizarse para propositos profilacticos o terapeuticos.
MXPA05013973A 2003-06-17 2004-06-17 Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. MXPA05013973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47939303P 2003-06-17 2003-06-17
PCT/US2004/019546 WO2005002621A2 (en) 2003-06-17 2004-06-17 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes

Publications (1)

Publication Number Publication Date
MXPA05013973A true MXPA05013973A (es) 2006-03-02

Family

ID=33563795

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013973A MXPA05013973A (es) 2003-06-17 2004-06-17 Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.

Country Status (12)

Country Link
US (1) US20050079152A1 (es)
EP (3) EP2246067B1 (es)
JP (2) JP5127224B2 (es)
AT (1) ATE476196T1 (es)
AU (1) AU2004253479B9 (es)
CA (1) CA2529057A1 (es)
DE (1) DE602004028468D1 (es)
DK (1) DK1635863T3 (es)
ES (1) ES2350043T3 (es)
MX (1) MXPA05013973A (es)
PL (1) PL1635863T3 (es)
WO (1) WO2005002621A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ZA200503511B (en) * 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
CA2570998A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Improved efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
MX2007008010A (es) * 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
JP2008543314A (ja) * 2005-06-17 2008-12-04 マンカインド コーポレイション エピトープ類似体
WO2006138568A2 (en) * 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
US20090117132A1 (en) * 2005-07-07 2009-05-07 Pfizer, Inc. Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
EP1792627A1 (en) * 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
PT2032163E (pt) 2006-06-15 2013-04-11 Novartis Ag Regime em multidoses de vacinação de influenza poupador de adjuvante
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP5755839B2 (ja) * 2007-02-15 2015-07-29 マンカインド コーポレイション Ｔ細胞応答の増強方法
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3533461A3 (en) * 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
EP3023436A1 (en) * 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
WO1998058956A2 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
EP2286831A1 (en) 1997-07-10 2011-02-23 Mannkind Corporation A method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
CA2721011A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
EP1372736A4 (en) 2001-03-07 2004-11-17 Mannkind Corp PREPARATIONS AGAINST CANCER FORMATION
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7076244B2 (en) 2001-07-23 2006-07-11 Research In Motion Limited System and method for pushing information to a mobile device
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP2314712B1 (en) 2001-11-07 2014-01-08 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
WO2004110485A1 (en) * 2003-06-13 2004-12-23 Palmowski Michael J Materials and methods for improved vaccination
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Also Published As

Publication number Publication date
DK1635863T3 (da) 2010-11-22
WO2005002621A3 (en) 2005-08-04
PL1635863T3 (pl) 2011-01-31
EP2246067B1 (en) 2017-02-15
JP5127224B2 (ja) 2013-01-23
EP1635863B1 (en) 2010-08-04
JP2013028619A (ja) 2013-02-07
AU2004253479B2 (en) 2011-09-01
ES2350043T3 (es) 2011-01-17
EP1635863A2 (en) 2006-03-22
AU2004253479A1 (en) 2005-01-13
AU2004253479B9 (en) 2011-10-06
WO2005002621A2 (en) 2005-01-13
EP2246067A2 (en) 2010-11-03
US20050079152A1 (en) 2005-04-14
CA2529057A1 (en) 2005-01-13
EP2246067A3 (en) 2011-07-13
EP2356999A1 (en) 2011-08-17
JP2007523863A (ja) 2007-08-23
DE602004028468D1 (de) 2010-09-16
ATE476196T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
IN2014DN08830A (es)
WO2006095330A3 (en) Methods and immunogenic cell preparations for treating antigen-associated diseases
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2005037190A3 (en) Multiplex vaccines
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
PL351893A1 (en) Vaccines
WO2007024941A3 (en) Polyvalent vaccine
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
WO2006055024A3 (en) Minicells as vaccines
GB0503936D0 (en) Method
WO2007016340A3 (en) Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
WO2003084467A3 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO2003066094A3 (en) Hepatitis b vaccines
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2003078595A3 (en) Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
MY127452A (en) Vaccines.

Legal Events

Date Code Title Description
FG Grant or registration